奥马利祖马布用于治疗多种食物过敏症
Robert A Wood1, Alkis Togias1, Scott H Sicherer1
1From the Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore (R.A.W., J.D., K.M.), and the National Institutes of Health (National Institutes of Allergy and Infectious Diseases), Bethesda (A.T., A.K.R.S., M.V., S.D.H., E.B., J.P., L.M.W.) - both in Maryland; the Division of Pediatric Allergy and Immunology, Jaffe Food Allergy Institute, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York (S.H.S., J.W., M.G.); the Division of Pediatric Allergy and Immunology and Food Allergy Center, Massachusetts General Hospital, Boston (W.G.S., D.P.); the University of North Carolina School of Medicine (E.H.K., C.A.K., M.K.) and Rho (A.C., C.M.H., N.H.R., N.Y.) - both in Chapel Hill; the University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock (S.M.J., A.M.S.); National Jewish Health, Denver (D.Y.M.L., B.J.L.); Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta (B.P.V., T.L.); the Department of Pediatrics, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas (J.A.B., C.P.); the Division of Allergy and Immunology, Department of Pediatrics at Perelman School of Medicine at University of Pennsylvania, Philadelphia (J.M.S., T.B.-W.); Genentech-Roche, South San Francisco (A.I., J.O.), and Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Palo Alto (S.B.S., A.L., R.S.C.) - both in California; and Novartis Pharmaceuticals, East Hanover, NJ (M.L.-S., A.U.).
奥马利祖马布治疗显著改善了儿童和青少年对多种食物过敏原的耐受性. 这提供了一个有前途的新方法来管理除了花生之外的严重食物过敏.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏和免疫学 过敏和免疫学
- 临床试验 临床试验
背景情况:
- 食物过敏很普遍,并导致严重的疾病.
- 口服免疫疗法是唯一批准的治疗方法,特别是对于花生过敏.
研究的目的:
- 评估奥马利祖马布作为多种食物过敏的单一疗法的疗效和安全性.
- 评估奥马利祖马布在增加对常见食物过敏原的反应值方面的潜力.
主要方法:
- 一项随机试验,涉及1-55岁的对花生和至少两种其他特定食物过敏的人.
- 参与者每隔2至4周接受皮下奥马利祖马布或安慰剂,持续16至20周.
- 主要终点:摄入600毫克花生蛋白,没有剂量限制症状;次要终点涉及果仁,牛奶和蛋.
主要成果:
- 接受奥马利祖马布治疗的67%的参与者达到主终点,而安慰剂治疗的7% (P<0.001).
- 对于次要终点观察到显著改善:果仁 (41%对3%),牛奶 (66%对10%) 和蛋 (67%对0%).
- 奥马利祖马布在一般情况下是安全的,注射部位反应是最常见的不良事件.
结论:
- 16周的奥马利祖马布治疗有效地增加了对花生和其他常见食物过敏原的反应值,对多种食物过敏的个体.
- 该研究表明,奥马利祖马布在儿科和青少年群体中比安慰剂优越.
- 结果表明,奥马利祖马布是治疗多种食物过敏的潜在治疗选择.


